<DOC>
	<DOCNO>NCT02450136</DOCNO>
	<brief_summary>This pilot study Pazopanib patient FGFR2 Amplification FGFR2 mutation Refractory solid tumor . This study single-arm , pilot study Pazopanib subject Refractory solid tumor harbor FGFR2 Amplification FGFR2 mutation Pazopanib 800mg administer orally day 28 days.Study treatment continue objective disease progression . To investigate efficacy Pazopanib subject Refractory solid tumor harbor FGFR2 Amplification FGFR2 mutation .</brief_summary>
	<brief_title>Single-arm Study Evaluate Safety Efficacy Pazopanib , Subjects With FGFR2 Amplification , FGFR2 Mutation Refractory Solid Tumors</brief_title>
	<detailed_description />
	<criteria>1 . Provision fully inform consent prior study specific procedure . 2 . Patients must ≥20 year age . 3 . FGFR2 amplification FGFR2 mutation Refractory Solid Tumors recur progress follow standard therapy , respond standard therapy , standard therapy . 4 . ECOG performance status 02 . 5 . Have measurable evaluate disease base RECIST1.1 . determine investigator . 6 . Adequate Organ Function Laboratory Values Absolute neutrophil count ≥ 1.5 x 109/L , Hemoglobin ≥ 9g/dL , Platelets ≥ 100 x 109/L bilirubin ≤ 1.5 x upper limit normal AST/ALT ≤ 2.5 x upper limit normal ( 5.0 X upper limit normal , subject liver metastasis ) creatinine ≤1.5 x UNL 7 . Patients childbearing potential use adequate contraceptive measure ( two form highly reliable method ) breast feed must negative pregnancy test prior start dose . 8 . Adequate heart function . 1 . Patients second primary cancer , except : adequately treat nonmelanoma skin cancer , curatively treated insitu cancer cervix , solid tumour curatively treat evidence disease ≤5 year . 2 . Has know active central nervous system ( CNS ) metastases . 3 . Has active infection require systemic therapy . 4 . Pregnancy breast feed 5 . Patients cardiac problem . 6 . Any previous treatment Pazopanib .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>